Levi & Korsinsky, LLP | Securities Class Action Attorneys

Upcoming Deadlines

Investors interested in taking an active role in litigation have a limited time to petition the court for appointment as lead plaintiff. If you are interested in acting as a lead plaintiff, submit your transactions before the deadline, and our analysts will calculate your losses. Don't wait till the last minute- discuss your options today.
View All Deadlines

Days Left

ZYXI

Zynex, Inc.

Deadline

May 19 2025

Class Period

3/13/23 - 3/11/25

Allegations

(1) Zynex shipped products, including electrodes, in excess of need; (2) as a result of this practice, the Company inflated its revenue; (3) the Company’s practice of filing false claims drew scrutiny from insurers, including the U.S. military health insurance program, Tricare; (4) as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

3/13/23 - 3/11/25

Deadline

May 19 2025

Learn More

Days Left

SANA

Sana Biotechnology, Inc.

Deadline

May 20 2025

Class Period

3/17/23 - 11/4/24

Allegations

(i) Sana was at significant risk of having insufficient funds to maintain its current operations and advance one or more of its product candidates; (ii) SC291 in oncology, SC379, and SG299 were less promising than defendants had led investors to believe; (iii) in order to preserve cash and advance its more promising product candidates, Sana was likely to decrease funding for and/or discontinue SC291 in oncology, SC379, and SG299, as well as significantly reduce its headcount; (iv) accordingly, defendants overstated Sana’s financial capacity to maintain its current operations and advance its existing product candidates; and (v) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

Class Period

3/17/23 - 11/4/24

Deadline

May 20 2025

Learn More

Days Left

PPTA

Perpetua Resources Corp.

Deadline

May 20 2025

Class Period

4/17/24 - 2/13/25

Allegations

According to the complaint, defendants provided investors with material information concerning Perpetua’s expected initial capital expenditure for the Stibnite Gold Project. Defendants’ statements included, among other things, minimization of the impact of inflation and other potential sources for increased capital expenditure costs for the project. On February 13, 2025, Perpetua published an updated cash flow model for the Stibnite Gold Project, unveiling additional capital expenses of $952 million, a more than 75% increase from the original figures presented to investors and well beyond the suggested 10-20% increase contemplated by defendants. The Company attributed these increased costs on inflation, indirect costs, higher mining costs, and direct decisions defendants made with respect to the project, including the choice to change the design of the electrical poles from timber to steel and the decision to “buy-and-build instead of lease the oxygen plant.” Following this news, the price of Perpetua’s common stock declined dramatically. From a closing market price of $11.97 per share on February 13, 2025, Perpetua’s stock price fell to $9.29 per share on February 14, 2025, a decline of about 22.39% in the span of just a single day.

Class Period

4/17/24 - 2/13/25

Deadline

May 20 2025

Learn More

Days Left

UCTT

Ultra Clean Holdings, Inc.

Deadline

May 23 2025

Class Period

5/6/24 - 2/24/25

Allegations

According to the complaint, defendants provided investors with material information concerning the elevated demand from Chinese original equipment manufacturers (OEMs) and in the general Chinese domestic market for Ultra Clean’s products throughout the fiscal year 2024. Defendants’ statements included, among other things, reports of increased demand for the Company’s products and services in the domestic Chinese market and reports of increased revenue, including revenue doubling with no signs of slowing down, due to the elevated demand in China for Ultra Clean’s products and services. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of the demand for Ultra Clean’s products and services in the domestic Chinese market; notably, that the Company was facing a customer ramp issue with one of its critical customers, as well as a combination of inventory and demand corrections, which, ultimately, caused weakness for Ultra Clean in China. On February 24, 2025, Ultra Clean published fourth quarter and full year 2024 fiscal results and hosted an associated earnings call, where the Company’s executives revealed that Ultra Clean was facing “demand softness” in China. In particular, Ultra Clean was facing decreased demand in China due to extended qualification timelines and inventory absorption. Investors and analysts reacted immediately to these revelations. The price of Ultra Clean’s common stock declined dramatically. From a closing market price of $36.06 per share on February 24, 2025, Ultra Clean’s stock price fell to $25.90 per share on February 25, 2025, a decline of over 28% in the span a single day.

Class Period

5/6/24 - 2/24/25

Deadline

May 23 2025

Learn More

Days Left

ATNM

Actinium Pharmaceuticals, Inc.

Deadline

May 27 2025

Class Period

10/31/22 - 8/2/24

Allegations

(1) the Company’s data from the Phase 3 Sierra trial was unlikely to satisfy the FDA’s guidelines for the acceptance and approval of the Company’s targeted radiotherapy, Iomab-B BLA; (2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival that the Company provided to the FDA in an attempt to mitigate the Sierra Trial’s poor OS data were unlikely to satisfy the FDA’s guidelines for the acceptance and approval of the Company’s Iomab-B BLA; (3) as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved; and (4), as a result, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

10/31/22 - 8/2/24

Deadline

May 27 2025

Learn More

Days Left

SOUN

SoundHound AI, Inc.

Deadline

May 27 2025

Class Period

5/10/24 - 3/3/25

Allegations

(i) the material weaknesses in SoundHound’s internal controls over financial reporting impaired the Company’s ability to effectively account for corporate acquisitions; (ii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal controls over financial reporting; (iii) as a result of the foregoing material weaknesses, SoundHound’s reported goodwill following the Amelia Acquisition was inflated and would need to be corrected; (iv) further, SoundHound would likely require extra time and expense to effectively account for the SYNQ3 and Amelia Acquisitions; (v) the foregoing increased the risk that the Company would be unable to timely file certain financial reports with the SEC; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

5/10/24 - 3/3/25

Deadline

May 27 2025

Learn More

Days Left

SEI

Solaris Energy Infrastructure, Inc.

Deadline

May 27 2025

Class Period

7/9/24 - 3/17/25

Allegations

On March 17, 2025, Morpheus Research released a report alleging that the company’s Power Solutions division is built on an overvalued acquisition involving an individual with a history of environmental crimes. Additionally, the report raises concerns about potential overreliance on a single major customer, undisclosed environmental regulatory risks, and questionable financial reporting practices. Following this news, shares of Solaris Energy Infrastructure, Inc. fell over 15% in intraday trading on that day.

Class Period

7/9/24 - 3/17/25

Deadline

May 27 2025

Learn More

Days Left

CGC

Canopy Growth Corporation

Deadline

June 3 2025

Class Period

5/30/24 - 2/6/25

Allegations

(i) Canopy had incurred significant costs producing Claybourne pre-rolled joints in connection with the Claybourne product launch in Canada; (ii) the foregoing costs, in addition to certain indirect costs that Canopy incurred in connection with its Storz & Bickel vaporizer devices, were likely to have a significant negative impact on the Company’s gross margins and overall financial results; (iii) accordingly, defendants had overstated the efficacy of Canopy’s cost reduction measures and the health of its gross margins while downplaying issues with the same; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

5/30/24 - 2/6/25

Deadline

June 3 2025

Learn More

Days Left

ECG

Everus Construction Group, Inc.

Deadline

June 3 2025

Class Period

10/31/24 - 2/11/25

Allegations

(1) the Company’s backlog conversion cycle had become elongated due to larger, more complex projects; (2) as a result, the Company’s revenue recognition would be delayed; and (3) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

10/31/24 - 2/11/25

Deadline

June 3 2025

Learn More

Days Left

VTRS

Viatris Inc.

Deadline

June 3 2025

Class Period

8/8/24 - 2/26/25

Allegations

According to the complaint, defendants provided investors with material information concerning the failed inspection of Viatris’ Indore, India facility. Defendants’ statements misrepresented the FDA’s issuance of a warning letter and its impact on Viatris' operations. Defendants routinely referred to the impact of the warning letter as a mere “minor headwind” for the Company. On February 27, 2025, Viatris announced its financial results for the fourth quarter and full fiscal year 2024 and provided disappointing fiscal 2025 guidance. The Company attributed below-expectation guidance on “the expected financial impact from Indore facility warning letter and import alert.” Following this news, the price of Viatris’ common stock declined dramatically. From a closing market price of $11.24 per share on February 26, 2025, Viatris’ stock price fell to $9.53 per share on February 27, 2025, a decline of about 15.21% in the span of just a single day.

Class Period

8/8/24 - 2/26/25

Deadline

June 3 2025

Learn More

Days Left

ABBV

Cerevel Therapeutics Holdings, Inc.

Deadline

June 3 2025

Class Period

This lawsuit is on behalf of all persons or entities that: (a) sold or otherwise disposed of the publicly-traded common stock of Cerevel during the period from October 11, 2023 through August 1, 2024, inclusive. (b) held shares of Cerevel as of the January 8, 2024 record date and were entitled to vote on the merger of Cerevel and AbbVie Inc. (c) sold shares of Cerevel stock contemporaneously with Bain Capital’s purchase of shares on or about October 16, 2023.

Allegations

According to the complaint, Cerevel’s October 16, 2023 secondary stock offering (the “October Offering” or “Offering”) documents and other public statements omitted material facts regarding AbbVie’s interest in acquiring Cerevel at a price well in excess of the $22.81 per share Offering price, artificially deflating Cerevel’s stock price until the merger was announced. Moreover, Cerevel’s controlling shareholder, Bain Capital Investors, LLC (“Bain”), acquired Cerevel shares from the October Offering at an artificially depressed price while allegedly in possession of material nonpublic information regarding AbbVie’s interest. On December 6, 2023, Cerevel publicly announced that AbbVie agreed to acquire Cerevel for $45 per share. The merger allowed Bain to receive a windfall of more than $120 million on the shares it acquired at the artificially depressed Offering price. In addition, Cerevel’s January 18, 2024 Proxy statement misled investors regarding the true nature and timing of AbbVie’s interest in Cerevel.

Class Period

Deadline

June 3 2025

Learn More

Days Left

TMCI

Treace Medical Concepts, Inc.

Deadline

June 10 2025

Class Period

5/8/23 - 5/7/24

Allegations

(1) competition impacted the demand for and utilization of its primary product, the 3D bunion correction system, the “Lapiplasty”; (2) as a result, Treace Medical’s revenue declined and the Company needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function); and (3) defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

5/8/23 - 5/7/24

Deadline

June 10 2025

Learn More

Days Left

BBAI

BigBear.ai Holdings, Inc.

Deadline

June 10 2025

Class Period

3/31/22 - 3/25/25

Allegations

(i) BigBear maintained deficient accounting review policies related to the reporting and disclosure of certain non-routine, unusual, or complex transactions; (ii) as a result, the Company incorrectly determined that the conversion option within the 2026 Convertible Notes qualified for the derivative scope exception under ASC 815-40 and failed to bifurcate the conversion option as required by ASC 815-15; (iii) accordingly, BigBear had improperly accounted for the 2026 Convertible Notes; (iv) the foregoing error caused BigBear to misstate various items in several of the Company’s previously issued financial statements; (v) as a result, these financial statements were inaccurate and would likely need to be restated; (vi) BigBear would require extra time and expense to correct the inaccurate financial statements, thereby increasing the risk that the Company would be unable to timely file certain financial reports with the SEC; and (vii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

3/31/22 - 3/25/25

Deadline

June 10 2025

Learn More

Days Left

IBTA

Ibotta, Inc.

Deadline

June 16 2025

Class Period

This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded Ibotta securities pursuant and/or traceable to documents issued in connection with Ibotta’s April 18, 2024 initial public offering.

Allegations

According to the filed complaint, defendants made false statements and/or concealed that they did not properly warn investors of the risks concerning Ibotta’s contract with The Kroger Co. (“Kroger”). Kroger’s contract was at-will, and Ibotta failed to warn investors that a large client could cancel their contract with Ibotta without warning. Despite providing a detailed explanation of the terms of Ibotta’s contract with Walmart, there was not a single warning of the at-will nature of Kroger’s contract. Rather than disclosing the very real risk of a major client walking away at any time, Ibotta provided boilerplate warnings concerning the importance of maintaining ongoing relationships with their clients.

Class Period

Deadline

June 16 2025

Learn More

Days Left

ZBIO

Zenas BioPharma, Inc.

Deadline

June 16 2025

Class Period

This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma’s September 2024 initial public offering.

Allegations

(1) Zenas BioPharma materially overstated the amount of time that it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and (2) as a result, defendants’ public statements were materially false and misleading at all relevant times and negligently prepared.

Class Period

Deadline

June 16 2025

Learn More

Days Left

NPWR

NET Power, Inc.

Deadline

June 17 2025

Class Period

6/9/23 - 3/7/25

Allegations

(i) Net Power was unlikely to complete its first utility-scale plant, Project Permian, on schedule and the project was likely to be significantly more expensive than defendants had represented, because of, inter alia, supply chain issues and numerous site- and region-specific challenges; (ii) accordingly, defendants’ projections regarding the time and capital needed to complete Project Permian were unrealistic; (iii) the increased time and capital needed to complete Project Permian were likely to have a significant negative impact on the Company’s business and financial results; and (iv) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

6/9/23 - 3/7/25

Deadline

June 17 2025

Learn More

Days Left

NSSC

Napco Security Technologies, Inc.

Deadline

June 24 2025

Class Period

2/5/24 - 2/3/25

Allegations

According to the complaint, defendants provided investors with material information concerning Napco’s overall expected growth and strength in the Company’s hardware division. Defendants’ statements included, among other things, confidence in Napco’s ability to achieve its fiscal 2026 growth projections on back of its ability to both appropriately forecast and execute upon the alleged demand for its hardware products. On February 3, 2025, Napco announced its financial results for the second quarter of fiscal 2025, revealing a significant reduction in hardware sales for the quarter. The Company attributed the decline “primarily … to reduced sales from 2 of the company’s larger distributors.” As a result of the setback in sales, defendants additionally pulled back their long-term 45% EBITDA margin target, as they “don’t know” if the target can be achieved by the end of fiscal 2026. Following this news, Napco’s common stock declined dramatically. From a closing market price of $36.70 per share on January 31, 2024, Napco’s stock price fell to $26.93 per share on February 3, 2025, a decline of about 26.62% in the span of just a single day.

Class Period

2/5/24 - 2/3/25

Deadline

June 24 2025

Learn More

Days Left

CAR

Avis Budget Group, Inc.

Deadline

June 24 2025

Class Period

2/16/24 - 2/10/25

Allegations

(i) Avis Budget crafted and implemented a plan to significantly accelerate its fleet rotation in the fourth quarter of 2024; (ii) the foregoing acceleration shortened the useful life of the majority of the Company’s vehicles in the Americas segment, thereby reducing their recoverable value; (iii) as a result, Avis Budget would be forced to recognize billions of dollars in impairment charges and incur substantial losses; (iv) all the foregoing was likely to, and did, have a significant negative impact on the Company’s financial results; (v) accordingly, Avis Budget’s financial and/or business prospects were overstated; and (vi) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Class Period

2/16/24 - 2/10/25

Deadline

June 24 2025

Learn More

Days Left

LPRO

Open Lending Corporation

Deadline

June 30 2025

Class Period

2/24/22 - 3/31/25

Allegations

According to the filed complaint, defendants made false statements and/or concealed that they: (1) misrepresented the capabilities of the Company’s risk-based pricing models; (2) issued materially misleading statements regarding the Company’s profit share revenue; (3) failed to disclose the Company’s 2021 and 2022 vintage loans had become worth significantly less than their corresponding outstanding loan balances; and (4) misrepresented the underperformance of the Company’s 2023 and 2024 vintage loans. As a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Class Period

2/24/22 - 3/31/25

Deadline

June 30 2025

Learn More

Days Left

CIVI

Civitas Resources, Inc.

Deadline

July 1 2025

Class Period

2/27/24 - 2/24/25

Allegations

(i) Civitas was highly likely to significantly reduce its oil production in 2025 as a result of, inter alia, declines following the production peak at the DJ Basin in the fourth quarter of 2024 and a low TIL count at the end of 2024; (ii) increasing its oil production would require the Company to acquire additional acreage and development locations, thereby incurring significant debt and causing the Company to sell corporate assets to offset its acquisition costs; (iii) the Company’s financial condition would require it to implement disruptive cost reduction measures including a significant workforce reduction; (iv) accordingly, Civitas’s business and/or financial prospects, as well as its operational capabilities, were overstated; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Class Period

2/27/24 - 2/24/25

Deadline

July 1 2025

Learn More

Days Left

WST

West Pharmaceutical Services, Inc.

Deadline

July 7 2025

Class Period

2/16/23 - 2/12/25

Allegations

(a) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin HVP portfolio; (b) West’s SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to the Company’s profit margins due to operational inefficiencies; (c) these margin pressures created the risk of costly restructuring activities, including the Company’s exit from continuous glucose monitoring contracts with longstanding customers; and (d) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis.

Class Period

2/16/23 - 2/12/25

Deadline

July 7 2025

Learn More

Days Left

UNH

UnitedHealth Group Incorporated

Deadline

July 7 2025

Class Period

12/3/24 - 4/16/25

Allegations

(1) UnitedHealth had, for years, engaged in a corporate strategy of denying health coverage in order to boost its profits, and ultimately, its share price; (2) this anti-consumer strategy resulted in regulatory scrutiny against UnitedHealth, which ultimately resulted in the murder of Brian Thompson; (3) animus towards UnitedHealth was such that, subsequent to the murder of Mr. Thompson, many Americans openly celebrated his demise, expressed admiration for his accused killer, and/or otherwise demanded that UnitedHealth change its strategy even if they condemned Mr. Thompson’s killing; (4) the foregoing regulatory and public outrage caused UnitedHealth to change its corporate practices; (5) notwithstanding the foregoing, UnitedHealth recklessly stuck with the guidance it issued the day before Thompson’s murder, which was unrealistic considering the Company’s changing corporate strategies; and (6) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

Class Period

12/3/24 - 4/16/25

Deadline

July 7 2025

Learn More

Days Left

DMRC

Digimarc Corporation

Deadline

July 7 2025

Class Period

5/3/24 - 2/26/25

Allegations

(1) a large commercial partner would not renew a large contract on the same terms; (2) as a result, Digimarc would renegotiate the large commercial contract; (3) based on this renegotiation, the Company’s subscription revenue and annual recurring revenue would be adversely affected; (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading or lacked a reasonable basis.

Class Period

5/3/24 - 2/26/25

Deadline

July 7 2025

Learn More

Days Left

CODI

Compass Group Diversified Holdings, LLC

Deadline

July 8 2025

Class Period

5/1/24 - 5/7/25

Allegations

According to the complaint, throughout the class period, defendants failed to disclose to investors that Compass lacked effective internal controls over its financial reporting; that Compass failed to disclose critical information regarding Lugano Holding, Inc. (“Lugano”) which kept undisclosed financing arrangements and exhibited irregularities in its sales, cost of sales, inventory and accounts receivable; and that, as a result of the foregoing, defendants’ positive statements about the Company’s financial reporting were materially misleading. The truth emerged on May 7, 2025, after the market closed, the Company announced that its financial statements for fiscal 2024 could no longer be relied upon due to an ongoing internal investigation into its subsidiary, Lugano. Specifically, Compass reported that its Audit Committee launched an investigation over “concerns about how Lugano was potentially financing inventory.” The Company also announced that it intends to delay the filing of its first quarter 2025 Form 10-Q. Further, effective May 7, 2025, Lugano’s founder and CEO, Moti Ferder, resigned from Lugano and will not receive any severance compensation. Following this news, the price of Compass’ common stock declined dramatically. From a closing market price of $17.25 per share on May 7, 2025 to $6.55 per share on May 8, 2025.

Class Period

5/1/24 - 5/7/25

Deadline

July 8 2025

Learn More

View All Deadlines

Never Miss a Potential Recovery Again

Sign up for Class Action Alerts

$456,500,000 in Total Settlement Funds Available. See if you qualify!Find Out More

We Give Shareholders A Voice.

Settlements

Who We Are

Find an Attorney

Find a Case

Upcoming Deadlines

ZYXI

Zynex, Inc.

SANA

Sana Biotechnology, Inc.

PPTA

Perpetua Resources Corp.

UCTT

Ultra Clean Holdings, Inc.

ATNM

Actinium Pharmaceuticals, Inc.

SOUN

SoundHound AI, Inc.

SEI

Solaris Energy Infrastructure, Inc.

CGC

Canopy Growth Corporation

ECG

Everus Construction Group, Inc.

VTRS

Viatris Inc.

ABBV

Cerevel Therapeutics Holdings, Inc.

TMCI

Treace Medical Concepts, Inc.

BBAI

BigBear.ai Holdings, Inc.

IBTA

Ibotta, Inc.

ZBIO

Zenas BioPharma, Inc.

NPWR

NET Power, Inc.

NSSC

Napco Security Technologies, Inc.

CAR

Avis Budget Group, Inc.

LPRO

Open Lending Corporation

CIVI

Civitas Resources, Inc.

WST

West Pharmaceutical Services, Inc.

UNH

UnitedHealth Group Incorporated

DMRC

Digimarc Corporation

CODI

Compass Group Diversified Holdings, LLC

News

CGC Investors Sue After Margins Let Down

Bad MER Buyout Sparks SEI Investors Lawsuit

Investors Pull Plug on SANA After Research Bombshell

Our World-Class Team

Sign up for Class
Action Alerts